Evidence map›Paper›PMID 35215337›Full record

ReviewPharmaceuticals (Basel, Switzerland)2022

Experimental Nuclear Medicine Meets Tumor Biology.

Theresa Balber, Loan Tran, Katarína Benčurová, Julia Raitanen, Gerda Egger, Markus Mitterhauser

Abstract readReview
In one paragraph

Review in Pharmaceuticals (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Radiobiological Assessment of Targeted Radionuclide Therapy with [International journal of molecular sciences · 2023
    Article
  2. The Role of Molecular Imaging in Personalized Medicine.Journal of personalized medicine · 2023
    Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Theresa BalberLudwig Boltzmann Institute Applied Diagnostics, 1090 Vienna, Austria.ORCID 0000-0002-8154-5680
Loan TranLudwig Boltzmann Institute Applied Diagnostics, 1090 Vienna, Austria.
Katarína BenčurováLudwig Boltzmann Institute Applied Diagnostics, 1090 Vienna, Austria.
Julia RaitanenLudwig Boltzmann Institute Applied Diagnostics, 1090 Vienna, Austria.ORCID 0000-0002-8115-3062
Gerda EggerLudwig Boltzmann Institute Applied Diagnostics, 1090 Vienna, Austria.ORCID 0000-0003-2489-155X
Markus MitterhauserLudwig Boltzmann Institute Applied Diagnostics, 1090 Vienna, Austria.ORCID 0000-0003-3173-5272

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Personalized treatment of cancer patients demands specific and validated biomarkers for tumor diagnosis and therapy. The development and validation of such require translational preclinical models that recapitulate human diseases as accurately as possible. Moreover, there is a need for convergence of different (pre)clinical disciplines that openly share their knowledge and methodologies. This review sheds light on the differential perception of biomarkers and gives an overview of currently used models in tracer development and approaches for biomarker discovery.

Indexed as

animal modelsbiomarker imagingcancer biomarkersin vitro modelsmolecular imagingmolecular pathologytracer development

Identifiers

PMID35215337
PMCPMC8878163

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.